<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02331602</url>
  </required_header>
  <id_info>
    <org_study_id>Kimura5656</org_study_id>
    <nct_id>NCT02331602</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran</brief_title>
  <acronym>RIVAL-AF</acronym>
  <official_title>Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yokohama City University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yokohama City University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yokohama City University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antiinflammatory effects of rivaroxaban compared
      with dabigatran in patients with atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous study showed that administration of rivaroxaban reduced expression of
      proinflammatory mediators in apolipoprotein E-deficient mice. However, it is unknown whether
      the anti-inflammatory markers are decreased in patients with atrial fibrillation receiving
      novel oral anticoagulants.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>median variation of inflammatory markers (including high sensitivity C reactive protein, pentraxin3, interleukin-6, and interleukin-18) between at baseline and 12 months later in each treatment group</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change over time of above inflammatory markers during 12 months follow-up period (at baseline, 1 month, 3 months, 6 months, and 12 months later) in each treatment group</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>frequency of 12-month adverse cardiac and cerebrovascular events (including cardiovascular death, myocardial infarction, revascularization, ischemic stroke and systemic embolism)and frequency of 12-month major bleeding (defined as ISTH criteria)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are assigned to receive rivaroxaban 15mg once daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are assigned to receive dabigatran 150mg twice daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Patients are assigned to receive rivaroxaban 15mg once daily for 12 months. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.</description>
    <arm_group_label>rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Patients are assigned to receive dabigatran 150mg twice daily for 12 months. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.</description>
    <arm_group_label>dabigatran</arm_group_label>
    <other_name>Pradaxa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-valvular atrial fibrillation

          -  a CHADS2-VASc score of 1 or more

        Exclusion Criteria:

          -  contraindication for rivaroxaban or dabigatran

          -  stroke or systemic embolism, acute coronary syndromes or peripheral artery disease
             within 6 months before enrollment

          -  acute heart failure

          -  severe chronic renal failure (creatinine clearance &lt; 30mL/min.)

          -  receiving dual antiplatelet therapy

          -  patients with a body weight of 50kg or less

          -  uncontrolled hypertension

          -  active malignancy, collagen disease, or infectious disease

          -  patients undergoing surgery within 6 months before enrollment

          -  patients who are planned to undergoing catheter ablation for atrial fibrillation

          -  patients who are not allowed to participate in the trial by judgement of the treating
             physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuo Kimura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yokohama City University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kengo Tsukahara, MD</last_name>
    <phone>81-45-261-5656</phone>
    <email>k-tsuka@urahp.yokohama-cu.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ashigara Kami Hospital</name>
      <address>
        <city>Ashigaura</city>
        <state>Kanagawa</state>
        <zip>258-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izumi Kobayashi, MD</last_name>
      <phone>81-465-83-0351</phone>
      <email>eno_r@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Izumi Kobayashi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chigasaki Municipal Hospital</name>
      <address>
        <city>Chigasaki</city>
        <state>Kanagawa</state>
        <zip>253-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atsushi Wada, MD</last_name>
      <phone>81-467-52-1111</phone>
      <email>Chigasaki-circ@hotmail.co.jp</email>
    </contact>
    <investigator>
      <last_name>Atsushi Wada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujisawa City Hospital</name>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <zip>251-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hideo Himeno, MD</last_name>
      <phone>81-466-25-3111</phone>
      <email>hdohimeno@jcom.home.ne.jp</email>
    </contact>
    <investigator>
      <last_name>Hideo Himeno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujisawa Shounandai Hospital</name>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <zip>252-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takahiro Takei, MD</last_name>
      <phone>81-466-44-1451</phone>
      <email>t_takei@fj-shounandai.or.jp</email>
    </contact>
    <investigator>
      <last_name>Takahiro Takei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadano Red Cross Hospital</name>
      <address>
        <city>Hadano</city>
        <state>Kanagawa</state>
        <zip>257-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reimin Sawada, MD</last_name>
      <phone>81-463-81-3721</phone>
      <email>rsawada@live.jp</email>
    </contact>
    <investigator>
      <last_name>Reimin Sawada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Sagamihara National Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0392</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yukiko Morita, MD</last_name>
      <phone>81-42-742-8311</phone>
      <email>y-morita@sagamihara-hosp.gr.jp</email>
    </contact>
    <investigator>
      <last_name>Yukiko Morita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nagatsuta kousei general hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>226-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takeshi Takamura, MD</last_name>
      <phone>81-45-981-1201</phone>
      <email>tkmrt@yokohama-cu.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takeshi Takamura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuo Kimura, MD</last_name>
      <phone>81-45-261-5656</phone>
      <email>c-kimura@urahp.yokohama-cu.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Kazuo Kimura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kengo Tsukahara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohama City Southern Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>234-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsutomu Endo, MD</last_name>
      <phone>81-45-832-1111</phone>
      <email>endotu@nanbu.saiseikai.or.jp</email>
    </contact>
    <investigator>
      <last_name>Tsutomu Endo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cardiovascular and Respiratory Disease Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuki Fukui, MD</last_name>
      <phone>81-45-701-9581</phone>
      <email>Fukui@kanagawa-junko.jp</email>
    </contact>
    <investigator>
      <last_name>Kazuki Fukui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yokohama Seamen's Insurance Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>240-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunichi Kobayashi, MD</last_name>
      <phone>81-45-331-1251</phone>
      <email>shunichi_kobayashi@sempos.or.jp</email>
    </contact>
    <investigator>
      <last_name>Shunichi Kobayashi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>International Goodwill Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>245-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Makoto Shimizu, MD</last_name>
      <phone>81-45-813-0221</phone>
      <email>makotoshimizuyaizu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Makoto Shimizu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teruyasu Sugano, MD</last_name>
      <phone>81-45-787-2800</phone>
      <email>t_sugano@yokohama-cu.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Teruyasu Sugano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yokosuka City hospital</name>
      <address>
        <city>Yokosuka</city>
        <state>Kanagawa</state>
        <zip>240-0195</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Okuda, MD</last_name>
      <phone>81-46-856-3136</phone>
      <email>jokudajun@yahoo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Jun Okuda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>International University of Health and Welfare Atami Hospital</name>
      <address>
        <city>Atami</city>
        <state>Shizuoka</state>
        <zip>413-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomohiko Shigemasa, MD</last_name>
      <phone>81-557-81-9171</phone>
      <email>tshig@iuhw.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Tomohiko Shigemasa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Omori Red Cross Hospital</name>
      <address>
        <city>Ohta</city>
        <state>Tokyo</state>
        <zip>143-8527</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasuyuki Mochida, MD</last_name>
      <phone>81-3-3775-3111</phone>
      <email>y-mochi@u01.gate01.com</email>
    </contact>
    <investigator>
      <last_name>Yasuyuki Mochida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2014</study_first_submitted>
  <study_first_submitted_qc>January 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>August 4, 2015</last_update_submitted>
  <last_update_submitted_qc>August 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yokohama City University Medical Center</investigator_affiliation>
    <investigator_full_name>Kiyoshi Hibi</investigator_full_name>
    <investigator_title>Associate Professor, Division of Cardiology</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

